AllianceBernstein’s Cidara Therapeutics CDTX Stock Holding History

AllianceBernstein’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-212,028	Closed	-$46.8M	–	3239
2025 Q4	$46.8M	Buy	212,028 +194,918	+1,139%	+$31.5M	0.01%	642
2025 Q3	$1.64M	Hold	17,110	–	–	﹤0.01%	2120
2025 Q2	$833K	Buy	+17,110	New	+$411K	﹤0.01%	2385

AllianceBernstein's CDTX Position: Q1 2026 in Review

AllianceBernstein sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 212,028 shares — an estimated $46.8M sold.

AllianceBernstein first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $46.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

AllianceBernstein reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
AllianceBernstein sold 212,028 Cidara Therapeutics shares in Q1 2026, an estimated $46.8M.
AllianceBernstein first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
AllianceBernstein's Cidara Therapeutics position peaked at $46.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.